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Abstract
Background: Sodium valproate (VPA) has been associated with a reduced risk of head and neck cancer
development. The potential protective mechanism of action is believed to be via inhibition of histone deacetylase
and subsequent epigenetic reprogramming. SAVER is a phase IIb open-label, randomised control trial of VPA as a
chemopreventive agent in patients with high-risk oral epithelial dysplasia (OED). The aim of the trial is to gather
preliminary evidence of the clinical and biological effects of VPA upon OED and assess the feasibility and
acceptability of such a trial, with a view to inform a future definitive phase III study.
Methods: One hundred and ten patients with high-risk OED will be recruited from up to 10 secondary care sites in
the UK and randomised into either VPA or observation only for 4 months. Women of childbearing potential will be
excluded due to the teratogenic properties of VPA. Tissue and blood samples will be collected prior to
randomisation and on the last day of the intervention/observation-only period (end of 4 months). Clinical
measurement and additional safety bloods will be taken at multiple time points during the trial. The primary
outcome will be a composite, surrogate endpoint of change in lesion size, change in grade of dysplasia and
change in LOH profile at 8 key microsatellite regions. Feasibility outcomes will include recruitment targets,
compliance with the study protocol and adverse effects. A qualitative sub-study will explore patient experience and
perception of the trial.
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Discussion: The current management options for patients with high-risk OED are limited and mostly include
surgical resection and clinical surveillance. However, there remains little evidence whether surgery can effectively
lead to a notable reduction in the risk of oral cancer development. Similarly, surveillance is associated with concerns
regarding delayed diagnosis of OED progressing to malignancy. The SAVER trial provides an opportunity to
investigate the effects of a repurposed, inexpensive and well-tolerated medication as a potential chemopreventive
strategy for patients with high-risk OED. The clinical and biological findings of SAVER will inform the
appropriateness, design and feasibility of a definitive phase III trial.
Trial registration: The trial is registered with the European Clinical Trials Database (Eudra-CT 2018-000197-30).
(http://www.isrctn.com/ISRCTN12448611). The trial was prospectively registered on 24/04/2018.
Keywords: Oral epithelial dysplasia, Sodium valproate, Epigenetic reprogramming, Drug repurposing, Randomised
controlled trial, Chemoprevention
Background
The incidence of oral squamous cell carcinoma (OSCC)
has been increasing for several decades and is predicted
to rise 33% by 2035 [1]. The disease results in notably
high rates of mortality and morbidity, with 50–60% 5-
year survival [2]. Most oral cancers are preceded by
long-standing clinical changes of the oral mucosa,
mainly white (leukoplakia) and red (erythroplakia)
patches, with progression from normal epithelium to in-
vasive OSCC occurring through sequential stages of
histological intra-epithelial changes including mild, mod-
erate, and severe dysplasia. A recent systematic review
suggests that OED is associated with oral cancer devel-
opment in 12.1% of cases, with severe OED showing
higher rates of progression compared to mild and mod-
erate dysplasia (24.1% vs 10.3%) [3]. Management of
OED should aim at reducing the risk of oral cancer de-
velopment; however, there remains little convincing evi-
dence that this can be achieved with any of the
treatment strategies currently adopted in clinical practice
[3–5]. OED is typically managed through surveillance or
surgical resection [4]; however, neither have strong evi-
dence to support their use nor address the underlying
pathogenesis. Surveillance is associated with concerns
regarding delayed diagnosis of OED progressing to
OSCC [2]. Surgery is not always possible for all lesions
or all patients, and recurrence rates for premalignant le-
sions range from 4 to 30% [6–9]. Also, localised therap-
ies fail to treat the wider mucosal field, often
encompassing the entire upper aerodigestive tract, and
therefore do not address the risk of multifocal synchron-
ous or metachronous dysplastic lesions. Accordingly,
there is an urgent unmet need to develop well-designed
clinical trials of novel interventions that, especially in
high-risk OED, could effectively reduce the risk of pro-
gression to malignancy.
This paper presents the protocol for the SAVER trial,
a multi-site, phase IIb, open-label, randomised control
trial of VPA in high-risk OED. This trial offers treatment
to patients with high-risk lesions who may otherwise
have no other option for active treatment and addresses
the need for further research in the area of chemopre-
vention treatment in OED [10]. This protocol report ad-
heres to SPIRIT guidance (Standard Protocol Items:
Recommendations for Interventional Trials) [11].
Evidence supporting the use of sodium valproate as a
chemopreventive agent for head and neck cancer
The Kang study is a cohort study of approximately 440,
000 patients in the US Veterans’ Affairs System, with
long-term psychiatric or neurological diagnoses and at
increased risk of smoking-related cancers; 26,000 had
been taking VPA for more than one year [12]. There
was a lower incidence of head and neck malignancy in
the group taking VPA, with a 32% protective effect re-
ported (HR 0.68, 95% CI 0.50–0.93). The reduction in
risk was maintained in a multivariate analysis for age,
sex, race, past vs current smoking, psychiatric or neuro-
logical disease, chronic obstructive pulmonary disease
and alcohol and substance use (HR 0.66, 95% CI 0.48–
0.92). The weight of this observation is reinforced by
dose effect, with both the length of treatment and dose
of VPA correlating with a further reduction of risk. The
most plausible mechanism of reduction of cancer risk is
through the epigenetic reprogramming effects of VPA
through histone deacetylase (HDAC) inhibition.
Rationale for the SAVER trial
The unmet need for an effective treatment to prevent
progression of OED to oral cancer, the risk-reduction ef-
fect demonstrated in the Kang study and the underlying
plausible epigenetic mechanisms underpin the need for a
clinical trial using VPA as an HDAC inhibitor in the
chemoprevention of oral cancer in individuals with high-
risk OED. HDACis are an emerging class of drugs that
have shown promise as anticancer agents when used
alone or in combination with conventional therapies.
HDACi and VPA have been comprehensively reviewed
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in their role in combination therapies, with either cyto-
toxic chemotherapy or targeted agents, in haemato-
logical malignancy or recurrent/metastatic solid tumours
[13, 14]. There is good evidence for clinical benefit of
epigenetic therapy in haematological pre-malignancies,
such as myelodysplastic syndromes [15]. In contrast, the
rationale for HDACi monotherapy in the setting of che-
moprevention for oral lesions presents a differing oppor-
tunity and there is a paucity of data. There is no in vivo
data related to HDACi in oral carcinogenesis; however,
there is in vitro evidence of the effect of HDACi on
growth inhibition and mediation of apoptosis of OSCC
cell lines [16–18]. There is also evidence of growth sup-
pression of xenograft tumours in nude mice [19].
Before embarking in a long and expensive phase III
trial, we suggest that preparatory research is needed in
order to (i) inform important aspects of the trial design
such as feasibility and outcome measures and (ii) identify
a preliminary signal of clinical efficacy linked to reason-
able biological mechanisms. We have therefore designed
a phase IIb trial so to gather data on such preliminary
evidence of effect, explore outcome measures and assess
the feasibility and acceptability of the trial in this
population.
It is expected that the clinical, mechanistic and feasi-
bility data of SAVER will inform the decision for a future
larger phase III trial with robust cancer (cancer develop-
ment) endpoints, necessitating much larger cohorts and
longer follow-up.
Methods and analysis
Study design and objectives
The SAVER trial is a phase IIb multicentre, open-label,
randomised control trial of VPA vs observation only in
patients with high-risk OED (see Table 1). The aim of
this trial is to investigate the effects of VPA as an epi-
genetic chemopreventive therapy in high-risk OED. The
primary objective is to determine: clinical activity of so-
dium valproate in high-risk OED, using a composite sur-
rogate endpoint of change in the size of clinical lesion,
changes in loss of heterozygosity profile and change in
grade of dysplasia (see the ‘Outcome measures’ section).
The key secondary objectives are to determine, in sub-
jects with high-risk OED: the mechanism of action of
VPA, associated toxicity, overall survival, development of
any cancer and the feasibility of conducting such re-
search in the UK National Health Service.
Recruiting centres
SAVER is coordinated by the Liverpool Clinical Trials
Centre (LCTC) and is sponsored by the University of
Liverpool.
Study population and inclusion criteria
Patients will be recruited via Oral Medicine, Oral and
Maxillofacial Surgery outpatient and Oral Dysplasia
Multidisciplinary clinics at the study sites. Eligible pa-
tients will have a lesion that is accessible, measurable (at
least 100 mm2), amenable to clinical photography and
located in the oral cavity or oropharynx or on the lip. As
part of the screening process for SAVER, all patients will
require an incisional biopsy of the index lesion to con-
firm eligibility; only patients with a biopsy confirming a
histopathological diagnosis of OED, considered to be at
high risk of transforming to oral cancer, will be included.
The definition of a high-risk lesion can be found in
Table 1.
There must be a treatment plan for either surgical re-
section or close monitoring (clinical and photographic
follow-up). The patient must be fully informed, have re-
ceived Patient Information Sheet (PIS) and considered
this during a ‘cooling-off’ period, be competent to con-
sent, age ≥ 18 and able to comply with minimum attend-
ance requirements. Exclusion criteria can be found in
Table 2.
Details of the management of patients being rando-
mised or having surgery within the SAVER trial during
the COVID-19 pandemic can be found in Additional file
1.
Randomisation
Randomisation will be completed centrally by the LCTC
via a password-protected web-based tool called the
Treatment Allocation Randomisation System (TARDIS).
All patients will be allocated a unique randomisation
number. Randomisation must be carried out within 90
days of the research biopsy report and commencement
of trial treatment within 30 days of the date of random-
isation. Patients will be randomised between VPA (arm
A) and observation only (arm B) in the ratio 2:1, with
site used as a stratification factor.
Table 1 Definition of a high-risk lesion
Definition of a high-risk lesion:
The index lesion is deemed at high risk of malignant transformation (i.e.
estimated >20% over 5 years) if:
a. Diagnosed as severe OED (WHO grade) or;
b. Diagnosed as mild or moderate OED (WHO grade), with at least one
additional high-risk feature(s) from the list below:
i. Patient is a non-smoker (less than 100 cigarettes or equivalent over
whole lifetime)
ii. Lesion size > 200 mm2
iii. Lateral tongue site
iv. Mucosal speckling or heterogeneous appearance
v. Patient had an excised OSCC during previous 5 years (but not within
previous 6 months).
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Arm A
VPA (Epilim) will initially be taken orally for 14 days at
a dose of 500 mg once daily. From day 15 until 4 calen-
dar months after day 1, VPA will be taken orally con-
tinuously at a dose of 500 mg twice daily. A 5-mm
punch biopsy will be taken at the 4-month time point.
Arm B
Patients in the control group will not receive any trial
medication. They will be monitored at the same intervals
as patients in Arm A (2, 4 and 6 months from baseline)
and will subject to the same blood monitoring schedule.
A 5-mm punch biopsy will be taken at the 4-month time
point, as for Arm A.
Schedule of events
Figure 1 shows the flow of patients through the trial and
the SPIRIT figure (Fig. 2) gives details of the procedures
required at each trial time-point. A screening biopsy (in-
cisional biopsy) is taken to confirm eligibility, prior to
randomisation. Patients are randomised to one of two
arms (sodium valproate or observation only), for 4
months. A repeat biopsy is taken on the final day of trial
medication at the 4-month time-point for both groups.
A clinical photograph and bloods are also taken at this
visit for both groups. In total the patient is examined five
times during the trial period for signs of lesion
progression.
Adverse events are monitored through the Liverpool
Adverse Events Reporting Questionnaire at 3 points dur-
ing the trial and at any unscheduled trial visits. All pa-
tients will have a full blood count, clotting screen and
LFTs performed as outlined in the schedule, to assess
for potential haematological and hepatic toxicities and
clotting aberrations.
Clinical progression during the trial
If a lesion is seen to have progressed and the clinician is
concerned regarding malignant transformation, an ur-
gent biopsy is requested and reported through the cen-
tral pathology unit at Newcastle Hospital. If the
diagnosis confirms malignant transformation, the patient
ceases study drug (if relevant) is withdrawn from the
trial and returns to normal clinical management and
follow-up. If histopathology does not show malignant
transformation, the patient returns to normal study
schedule or normal standard of care.
Outcome measures
Primary outcome measure
Response to treatment will be measured using a sur-
rogate endpoint. It is not feasible to use ‘malignant
transformation’ as an endpoint in this context, as a
large, long-term study would be required to allow
sufficient time for enough events to occur for statis-
tical power. The primary endpoint itself will be de-
rived as a composite score of changes in lesion size,
changes in histological grade and loss of heterozy-
gosity (LOH), which is advised in the context of rare
events.
Assessment of lesion size
Lesion size will be calculated based on the estimated el-
liptical area given by the longest length of the lesion and
Table 2 Exclusion criteria for the SAVER trial
Exclusion criteria
1. Synchronous or metachronous OSCC (i.e. at time of screening or
within 6 months)
2. Active malignancy outside head and neck region (with exception of
non-melanoma skin cancer)
3. Currently positive for COVID-19 (patients who have recovered from
COVID-19 are NOT excluded)
4. OSCC susceptible conditions e.g. Fanconi anaemia, Blooms
syndrome, ataxia-telangectasia and Li-Fraumeni syndrome
5. Clinical and/or histopathological diagnosis of oral submucous fibrosis
6. Immunosuppression. However, low dose i.e. < 10mg/day
prednisolone, or equivalent steroid, (as per BNF conversion table), are
not considered an exclusion.
7. Chronic previous or current use of sodium valproate
8. Diagnosed epilepsy that has chronic previous or current use of any
antiepileptic therapy
9. Obesity (body mass index ≥ 30)
10. Known relative or absolute contraindications to Sodium Valproate
(as listed in British National Formulary), and specifically:
a. Acute porphyria
b. Known or suspected mitochondrial disorders
c. Personal or family history of severe hepatic dysfunction, current
hepatic dysfunction (as evidenced by LFTs outwith reference range and
prolonged prothrombin time)
d. Past history or current pancreatitis
e. Women with child-bearing potential. A woman is considered of
childbearing potential (WOCBP), i.e. fertile, following menarche and until
becoming post-menopausal unless permanently sterile. Permanent steril-
isation methods include hysterectomy, bilateral salpingectomy, and bi-
lateral oophorectomy.
f. Potential drug interactions (particularly antipsychotic and
anticonvulsant medications, MAO inhibitors, antidepressants,
benzodiazepines), specifically patients taking phenobarbital, primodone,
carbopenem antibiotics (imipenem, panipenem, meropenem),
cimetidine, erythromycin, lamotrigine, olanzapine, pivmecillinam, sodium
oxybate, zidovudine, carbamazepine, phenytoin, rifampicin, high dose
salicylates including aspirin > 75 mg daily (patients taking low dose
aspirin 75 mg daily are eligible).
g. Patients with suicidal ideation and behaviour should be excluded
from the trial. Patients should also be monitored for signs of suicidal
ideation and behaviours and appropriate treatment should be
considered.
h. Patients with known or suspected mitochondrial disease, systemic
lupus erythematosus or hyperammonaemia
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the associated perpendicular width. Lesion size response
will be then measured on a 7-point scale ranging from −
3 to 3 based on the change in lesion size between pre
and post-treatment assessment (Table 3).
Assessment of histology response score
A 9-point scale will be used to obtain the histological
score as related to the grade of dysplasia. The histology
response score is the original pathology score minus the
final pathology score (from the specimen obtained at the
end of the 4-month treatment period). See Table 4.
Assessment of loss of heterozygosity (LOH) response score
LOH has been identified as a prognostic marker for pro-
gression of OED, with lesions displaying LOH at 3p and
9p having a 22-fold increased risk of progression to
OSCC [20]. The following 8 loci and associated genes
have been selected based on previous evidence of their
predictive value in the progression of OED:
 3p14 [D3S1007 (VHL), D3S1234 (FHIT)]
 9p21 [D9S171, D9S1748 (P16/CDKN2A), D9S1751
(P16)]
 9p22 (IFN-a)
 17p13 [D17S786 (P53) and TP53]
For each loci, a score of +1 is given if it is positive for
LOH and zero if it is negative for LOH. The LOH re-
sponse score will be the pre-treatment score minus the
post-treatment score.
Fig. 1 Patient activity through the SAVER trial
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Total responsiveness score
The total responsiveness score for each patient will be
calculated as follows: lesion size response score + histo-
logical response score + LOH response score. Patients
will be classified as ‘disease progression’ with a response
score ≤ − 1, ‘stable disease’ with a response score be-
tween − 1 and 1 and ‘response to treatment’ with a re-
sponse score ≥ 1. The only exception to these criteria is
for patients with confirmed malignant transformation.
These patients shall automatically be categorised as hav-
ing disease progression, irrespective of their responsive-
ness score. The disease response rate will compare
patients with response to treatment against patients with
either stable disease or disease progression.
Fig. 2 Spirit figure
Table 3 Scale for measuring change in the size of clinical lesion
Change in lesion size Code
≥ 75% decrease 3
50–74 % decrease 2
25–49% decrease 1
0–24% decrease or increase 0
25–49% increase − 1
50–74% increase − 2
≥ 75% increase − 3
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Secondary outcome measure
Secondary endpoints will be assessed including toxicity
(measured using Common Terminology Criteria for Ad-
verse Events (CTCAE) v4.03 classification), overall sur-
vival and malignancy of the head and neck (or other
sites) during the patient’s active trial period and for the
total duration of the trial. Feasibility endpoints will be
recorded, defined by overall and centre-specific rate of
recruitment, compliance with treatment, protocol devia-
tions and drop-out rates.
Mechanistic sub-study
VPA has a known mechanism of action as a histone dea-
cetylase inhibitor (HDACi). The reduced risk of head
and neck cancers demonstrated in patients taking VPA
has been hypothesised to be through epigenetic repro-
gramming of oral potentially malignant disorders [12].
As part of an embedded mechanistic sub-study, we will
assess tissue-specific epigenetic changes, changes in gene
expression, expressed markers of proliferation, apoptosis
and senescence. We will also assess pharmacodynamic
biomarkers of histone acetylation in circulating white
cell DNA, from venous blood samples taken at the 2-
and 4-month time points. The presence of a control
group will enable us to determine whether these effects
are specific to VPA. Tissues samples will be obtained be-
fore and after drug treatment. Samples will be bisected
and half used for histology and immunohistochemistry
and half used for RNA/DNA preparation.
Qualitative sub-study: the SAVER information study
This is the first UK-based chemoprevention trial in
OED, therefore we will explore patients’ perspectives on
the acceptability of SAVER and their experience of re-
cruitment and participation in the trial. This will be
achieved through 20 qualitative interviews, or until data
saturation is reached. The aim is to improve patient in-
formation resources and to enhance the design and ac-
ceptability of a future phase III trial. We will interview
patients who declined to participate in the trial and
those who took part; we will aim for diversity in key
characteristics: demographics, trial site and proposed
treatment (surgery vs surveillance).
Sample size calculation
Sample size calculations are carried out on the principles
of a single-stage Jung design for randomised phase II
studies based on exact binomial probabilities and allow-
ing for unequal allocation [21]. The primary outcome is
the response rate; a rate of 20% is estimated for the con-
trol arm with a 20% rate increase in the treatment arm
representing the minimal clinically important difference.
With a type I error of 0.16 and 82% of power, 100 pa-
tients (33 in the observation-only arm and 67 in the
treatment arm) will be required in the study. Adjusting
for a potential 10% drop-out rate, the final sample size
will be of 110 patients (37 in the observation-only arm
and 73 in the treatment arm).
The intent of the study will be to recruit the 110 pa-
tients required over a period of 32 months, assuming 10
sites recruiting at an average rate of 0.4 patients per site
per month.
Blinding
SAVER is an open-label trial. The primary endpoint of
the trial consists of objective assessments of lesion size
using a clinical photograph, grade of dysplasia and loss
of heterozygosity studies. These will all be assessed by
blinded assessors.
Statistical analysis
There will be no formal stopping rules or interim ana-
lysis based on patients’ response rate. However, an Inde-
pendent Safety and Data Monitoring Committee (ISDM
C) will meet at regular intervals to review and assess the
conduct of the study and the accumulated data. The
ISDMC will be able to make appropriate recommenda-
tions to the Trial Steering Committee (TSC) on grounds
of toxicity and feasibility.
The study will be analysed and reported in line with
the Consolidated Standards of Reporting Trials (CON-
SORT). Statistical analyses will be carried out following
the intention to treat principle (ITT), with the exception
of toxicity which will be analysed on the basis of the ac-
tual treatment received. Missing data are not anticipated
to be substantial in the study and therefore the final ana-
lysis shall be performed on a complete case basis. How-
ever, if more than 10% missing data are observed on the
primary outcome, multiple imputation technique by
chained equations shall be used.
Continuous variables will be summarised as median
and interquartile range and categorical variables will be
presented as frequencies of counts with associated per-
centages. Primary analysis on the primary outcome will
Table 4 Histological scoring scale
Score Histological diagnosis
0 Normal with or without hyperkeratosis






7 Carcinoma in situ
8 Invasive squamous cell carcinoma
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be performed using a stratified Mantel Haenszel test and
results will be assessed with a one-sided p value of 0.16
as the threshold for statistical significance. The primary
efficacy parameter (odds ratio) will also be reported with
the one-sided 84% confidence interval. Logistic regres-
sion will be used to investigate the relationship of the
primary outcome with key prognostic covariates. Ana-
lyses of categorical secondary outcome will mirror that
of response rate, using stratified Mantel Haenszel test
and logistic regression techniques. Time to event data
will be compared between arms by stratified log-rank
test. Further analyses on survival data shall be carried
out using Cox models if, after inspection of Schoenfeld
residuals, the proportional hazard assumption is not vio-
lated. All secondary analyses will be assessed by the
nominal two-sided p value of 0.05 to determine statis-
tical significance.
Ethical considerations
The trial protocol has been reviewed and approved by
North West - Haydock Research Ethics Committee and
REC reference: 18/NW/0180. The trial has been regis-
tered with the MHRA; the ISRCTN number is
12448611.
Sodium valproate safety profile
Sodium valproate is licensed for use in epilepsy and bi-
polar disorder. It is also used off-label for depression,
neuropathic pain, dementia and migraine. Very common
adverse effects, defined as occurring in >10% of patients,
include nausea and tremor. Common adverse events (be-
tween 1 and 10% of patients) include upper abdominal
cramps, transient increase in liver enzymes, weight gain
and diarrhoea, transient alopecia, reduced bone density,
thrombocytopenia and anaemia. Neurological adverse ef-
fects such as fatigue, sedation, confusion and dizziness
are also observed commonly. Due to the significant risk
of birth defects and developmental disorders in babies
born to mothers taking VPA during pregnancy, the
MHRA have issued guidance advising: ‘Valproate medi-
cines must no longer be used in women or girls of child-
bearing potential unless a Pregnancy Prevention
Programme is in place’. Women of childbearing poten-
tial (WOCBP) will not be recruited to the trial, due to
known teratogenic effects of VPA [22]. All women will
require a follicular stimulating hormone (FSH) test prior
to randomisation, to confirm post-menopausal status.
The exception to this is women who have undergone
total hysterectomy or bilateral salpingo-oophorectomy.
The SAVER trial will use VPA at 1000 mg/day; this is
a low to medium dose, associated with mild or absent
toxicities, and is well tolerated [23]. Higher doses, some-
times justified in epilepsy, are associated with weight
gain, tremor, drowsiness and cognitive slowing. In the
context of premalignant oral conditions, we feel that
these would not be justified. The impact of weight gain
will be reduced by excluding obese patients (BMI > 30).
Potential risks of delay to surgical treatment
Study participants who are listed for surgical excision of
OED will have their surgery scheduled at the end of
month 4 of the study. This is considered an acceptable
timeframe as the progression of OED to invasive cancer
is reported to take an average of 4 years from diagnosis
[3]. It is also in keeping with common clinical practice
at most HNC services in the UK, which prioritise treat-
ment of invasive oral cancer [24].
Criteria for discontinuing or modifying allocated
interventions
Patients may be withdrawn from treatment for any of
the following reasons: Development of an OSCC, un-
acceptable toxicity, any change in the patient’s medical
condition that justifies discontinuation of treatment in
the clinician’s opinion and pregnancy.
Treatment may be discontinued for any toxicity with a
significant impact on quality of life (generally grade 2 or
higher; however, persistent grade 1 adverse events (AEs)
may also lead to discontinuation). A 50% dose reduction
(500 mg/day) may also be considered for persistent
grade 1 toxicities rather than withdrawal from the trial.
Patients discontinuing due to toxicity will be followed
up and assessed as per protocol. Patients discontinuing
treatment for any reason will continue to be followed up
unless the patient explicitly withdraws consent for
follow-up. If the patient explicitly states their wish not
to contribute further data to the study, a withdrawal
CRF will be completed. Anonymised data collected up to
this point can still be used for study purposes.
Assessment of compliance with study treatment
All patients will have plasma valproate levels measured
at 2 months and 4 months; this will confirm that pa-
tients in the observation-only arm are not taking sodium
valproate and will help to confirm patient compliance in
the treatment arm. In addition, patients in the treatment
arm will be given a drug diary sheet to be completed
each day. Research Nurses will collect the unused tablets
and completed diaries and record any circumstances of
non-compliance in the patient notes and on the CRF.
The returned medication will be sent to the site phar-
macy for storage.
Recruitment
The main feasibility outcome is the recruitment rate.
Ten sites have been selected to allow an achievable re-
cruitment rate of 0.4 patients per site per month (ap-
proximately 4 patients per month) with a total of 110
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patients. Targets for recruitment will be set at 43 and 88
for 12 and 24 months respectively. As a guide, it is pro-
posed that if the study will be recruiting within 80% of
the intended rate (at least 34 and 70 for 12 and 24
months, respectively) then no action will be taken. If the
study is recruiting between 50% and 80% (between 22–
33 and 44–69 for 12 and 24 months, respectively) of the
intended rate, the ISDMC may recommend continuation
only if strategies will be put in place to increase recruit-
ment. If the study is recruiting at less than 50% (less
than 22 and 44 for 12 and 24 months, respectively) of
the intended rate, the ISDMC may recommend early ter-
mination of the study on the grounds of feasibility.
Adverse events
All adverse events that occur from the point of the pa-
tient’s written informed consent are to be reported, even
if the patient has not started taking VPA. All adverse
events should be reported up to the point of the primary
endpoint being established, with the exception of malig-
nant transformation or new head and neck cancer,
which should be collected until trial closure. All non-
serious adverse events (AE)/adverse reactions (AR),
whether expected or not, will be recorded in the relevant
page of the CRF. Serious adverse reactions (SARs), ser-
ious adverse events (SAEs) and suspected unexpected
serious adverse reactions (SUSARs) should be reported
within 24 h of the local site becoming aware of the
event. The SAE form asks for the nature of event, date
of onset, severity, corrective therapies given, outcome
and causality. The responsible investigator should sign
the causality of the event. Additional information should
be sent within 5 days if the reaction has not resolved at
the time of reporting. The LCTC will notify the MHRA
and main Research Ethics Committee (REC) of all SUSA
Rs occurring during the study according to the following
timelines; fatal and life-threatening within 7 days of noti-
fication and non-life-threatening within 15 days. All in-
vestigators will be informed of all SUSARs occurring
throughout the study. Local investigators should report
any SUSARs and/or SAEs as required by their Local Re-
search Ethics Committee and/or Research and Develop-
ment Office.
Confidentiality
Individual participant medical information obtained
through this study is considered confidential and disclos-
ure to third parties is prohibited. Case report forms will
be labelled with patient initials and unique trial random-
isation number. Tissue samples will be transferred to
both the pathology and GCLP laboratories and will be
identifiable by unique trial randomisation number only.
Consent forms sent to the LCTC as part of the random-
isation process may contain patient identifiers for
monitoring as described in the trial risk assessment.
Such information will be stored separately from the pa-
tient folders in secure, locked cabinets. Each participat-
ing site will maintain appropriate medical and research
records for this trial, in compliance with the
International Council for Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use (ICH) E6 Good Clinical Practice (GCP),
Section 4.9 and regulatory and institutional require-
ments for the protection of confidentiality of subjects.
Qualitative sub-study: the SAVER information study
Audio-recordings of semi-structured interviews will be
transferred to a professional transcription agency, with a
legally binding confidentiality agreement, via a secure
upload facility. Completed transcripts will be checked by
the qualitative researcher on receipt and pseudo-
anonymised ready for analysis. Audio recordings of the
interviews will be retained in case of queries until the
end of the study at which point the recordings will be
destroyed.
Audit
The SAVER investigational sites, facilities, laboratories
and all data (including sources) and documentation
must be available for GCP audit and inspection by com-
petent or independent ethics committees and the LCTC.
Such audits/inspections may take place at any sites
where trial-related activity is taking place (i.e. the Spon-
sor site(s), LCTC or at any investigators site, including
laboratories, pharmacies etc.). The site staff shall assist
in all aspects of audit or inspection. The LCTC has an
internal audit programme which will be produced annu-
ally by the LCTC Quality Assurance (QA) Manager. The
LCTC operate a risk-based audit programme, based on
the assessment of risks associated with both processes
with the quality system and the specific trials.
Data collection and data management
Trial data for SAVER will be captured using an elec-
tronic case report form (eCRF), with the exception of
randomisation, AEs and SAEs which will be processed
on paper CRF. The SAVER Data Management Plan Data
provides detailed information on data entry, coding, se-
curity and storage arrangements. The LCTC is housed
in a building that is secured by swipe card access for
authorised personnel and is locked when unattended.
Documents are kept in locked cabinets.
Protocol amendments
Plans for communicating important protocol modifica-
tions are detailed in LCTC’s document ‘Making Substan-
tial and Non-substantial amendments.’ All protocol
amendments will be communicated with the Sponsor,
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funder, research sites, patient representatives and all
other key stakeholders as agreed in trial-specific con-
tracts. Protocol amendments will only be implemented
at research sites following the receipt of the necessary
regulatory approvals. The LCTC ensures the receipt of
amendment documentation from individual research
sites.
Dissemination and access to data
The results of this trial will be submitted for publication
in relevant peer-reviewed publications and a plain Eng-
lish version, co-edited by patients, will be circulated to
all trial participants. Results (including negative results)
will be presented at national and international confer-
ences. We do not have formal plans to share anon-
ymised individual participant-level data.
Ancillary and post-trial care
NHS Trust and Non-Trust Hospitals have a duty of care
to patients treated, whether or not the patient is taking
part in a clinical trial, and they are legally liable for the
negligent acts and omission of their employees. Com-
pensation is therefore available in the event of clinical
negligence being proven.
Roles and responsibilities
Trial oversight and regulatory arrangements
Trial Management Group (TMG)
This comprises the chief investigator, other lead investi-
gators (clinical and non-clinical), patient representative
and members of the LCTC. The TMG will be respon-
sible for the day-to-day running and management of the
trial and will meet at least three times per year.
Independent Safety and Data Monitoring Committee (ISDM
C)
The independent Safety and Data Monitoring Commit-
tee (ISDMC) consists of an independent chairperson in
a related area of expertise, plus 2 independent members,
one of whom is also an expert in a related area and an-
other who is an expert in medical statistics. The ISDMC
will be responsible for reviewing and assessing recruit-
ment, interim monitoring of safety and effectiveness,
trial conduct and external data. The ISDMC will first
convene before the trial opens to recruitment and will
then define frequency of subsequent meetings (at least
annually). The ISDMC will provide a recommendation
to the TSC concerning the continuation of the study.
Trial Steering Committee (TSC)
The Trial Steering Committee will consist of an inde-
pendent chairperson, other independent experts in the
field of oral cancer, a statistician and at least one patient
representative. The role of the TSC is to provide overall
supervision for the trial and provide advice through its
independent Chairman. The ultimate decision for the
continuation of the trial lies with the TSC.
Sponsorship SAVER is sponsored by the University of
Liverpool and coordinated by the LCTC in the Univer-
sity of Liverpool. The trial Sponsor has authority in all
aspects of trial activities.
Registration The SAVER trial is registered with the
European Clinical Trials Database (Eudra-CT 2018-
000197-30)
Clinical trial suthorisation The trial has received clin-
ical trial authorization by the Medicines and Healthcare
Products Regulatory Authority (MHRA) under the Med-
icines For Human Use (Clinical Trials) Regulations
2004: 04196/0048/001-0001.
Discussion
This study protocol describes a multi-site, open-label
randomised control trial of VPA vs observation only in
the management of high-risk OED. There is an unmet
need for additional strategies in the management of
OED. Patients are currently offered surgery or close sur-
veillance, neither of which have sufficient supporting evi-
dence for the prevention of malignant transformation of
OED. Efforts in chemoprevention of malignant trans-
formation of OED have been limited and this represents
the first trial of VPA as a chemopreventive agent in
OED. The SAVER trial will investigate the clinical activ-
ity of VPA, using a composite endpoint of clinical,
pathological and molecular changes. The mechanism of
action will be explored using gene expression studies, in-
vestigation of epigenetic changes and expression of
markers of cell cycle regulation. Feasibility of recruit-
ment and patient perception of this type of trial will be
assessed through interviews of patients approached for
recruitment in the hope of informing the design of a fu-
ture Phase III clinical trial.
Trial Status
The SAVER trial is open (with a temporary halt to re-
cruitment due to the COVID-19 pandemic). The current
Protocol Version Number is 9 (date: March 2021). Re-
cruitment began on 17/12/2019 and the study is due to
complete in July 2023.
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